Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIIB, randomized trial of open-label efavirenz or atazanavir with ritonavir in combination with double-blind comparison of emtricitabine/tenofovir or abacavir/lamivudine in antiretroviral-naive subjects.

Trial Profile

A phase IIIB, randomized trial of open-label efavirenz or atazanavir with ritonavir in combination with double-blind comparison of emtricitabine/tenofovir or abacavir/lamivudine in antiretroviral-naive subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2018

At a glance

  • Drugs Atazanavir (Primary) ; Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/abacavir (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections
    • 01 Sep 2017 Results assessing the association between efavirenz metabolizer genotype and suicidality using pooled data from four clinical trials (A5095, A5142 ,A5175, A5202), published in the Journal of Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top